University of Limerick Institutional Repository

LRG1 expression is elevated in the eyes of patients with neovascular age-related macular degeneration

DSpace Repository

Show simple item record Mundo, Lucia Tosi, Gian Marco Lazzi, Stefano Pertile, Grazia Parolini, Barbara Neri, Giovanni Posarelli, Matteo De Benedetto, Elena Bacci, Tommaso Silvestri, Ennio Siciliano, Maria Chiara Barbera, Stefano Orlandini, Maurizio Greenwood, John Moss, Stephen E. Galvagni, Federico 2021-09-15T11:31:46Z 2021-09-15T11:31:46Z 2021
dc.description peer-reviewed en_US
dc.description.abstract Leucine-rich a-2-glycoprotein 1 (LRG1) is a candidate therapeutic target for treating the neovascular form of age-related macular degeneration (nvAMD). In this study we examined the expression of LRG1 in eyes of nvAMD patients. Choroidal neovascular membranes (CNVMs) from patients who underwent submacular surgery for retinal pigment epithelium–choroid graft trans plantation were collected from 5 nvAMD patients without any prior intravitreal anti-VEGF injection, and from six patients who received intravitreal anti-VEGF injections before surgery. As controls free of nvAMD, retina sections were obtained from the eyes resected from a patient with lacrimal sac tumor and from a patient with neuroblastoma. CNVMs were immunostained for CD34, LRG1, and α-smooth muscle actin (α-SMA). Aqueous humor samples were collected from 58 untreated-naïve nvAMD patients prior to the intravitreal injection of anti-VEGF and 51 age-matched cataract control patients, and LRG1 concentration was measured by ELISA. The level of LRG1 immunostaining is frequently high in both the endothelial cells of the blood vessels, and myofibroblasts in the surround ing tissue of CNVMs of treatment-naïve nvAMD patients. Furthermore, the average concentration of LRG1 was significantly higher in the aqueous humor of nvAMD patients than in controls. These observations provide a strong experimental basis and scientific rationale for the progression of a therapeutic anti-LRG1 monoclonal antibody into clinical trials with patients with nvAMD. en_US
dc.language.iso eng en_US
dc.publisher MDPI en_US
dc.relation.ispartofseries International Journal of Molecular Sciences;22 (16), 8879
dc.subject LRG1 en_US
dc.subject age-related macular degeneration en_US
dc.subject AMD en_US
dc.subject VEGF en_US
dc.subject choroidal neovascular membranes en_US
dc.title LRG1 expression is elevated in the eyes of patients with neovascular age-related macular degeneration en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US
dc.identifier.doi 10.3390/ijms22168879
dc.contributor.sponsor Ministero dell’Istruzione, dell’Università e della Ricerca en_US
dc.contributor.sponsor Department of Biotechnology, Chemistry and Pharmacy en_US
dc.contributor.sponsor Institute for Research, Training, and Rehabilitation en_US
dc.relation.projectid 2747, 08/08/2019 en_US
dc.relation.projectid 206413/B/17/Z en_US
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


My Account